1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
Delayed Nasdaq  -  04:00 2022-07-06 pm EDT
63.54 USD   -1.17%
09:05aNovavax Nuvaxovid COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17
AQ
07/05SECTOR UPDATE : Health Care Stocks Struggle Tuesday
MT
07/05SECTOR UPDATE : Health Care Stocks Retreating in Tuesday Trade
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
51.85(c) 51.43(c) 57.15(c) 64.29(c) 63.54 Last
4 113 231 3 556 907 6 423 652 7 175 284 5 869 935 Volume
+1.55% -0.81% +11.12% +12.49% -1.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 4 384 M - -
Net income 2022 2 019 M - -
Net cash position 2022 2 508 M - -
P/E ratio 2022 2,57x
Yield 2022 -
Sales 2023 3 086 M - -
Net income 2023 916 M - -
Net cash position 2023 3 354 M - -
P/E ratio 2023 6,09x
Yield 2023 -
Capitalization 5 023 M 5 023 M -
EV / Sales 2022 0,57x
EV / Sales 2023 0,54x
Nbr of Employees 1 541
Free-Float 98,8%
More Financials
Company
Novavax, Inc., along with its wholly owned subsidiaries, Novavax AB and Novavax CZ, is a biotechnology company. The Company promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address... 
More about the company
Ratings of Novavax, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about NOVAVAX, INC.
09:05aNovavax Nuvaxovid COVID-19 Vaccine Conditionally Authorized in the European Union for A..
AQ
07/05SECTOR UPDATE : Health Care Stocks Struggle Tuesday
MT
07/05SECTOR UPDATE : Health Care Stocks Retreating in Tuesday Trade
MT
07/05Novavax Says COVID-19 Vaccine Conditionally Authorized in the EU for Adolescents
MT
07/05Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Unio..
PR
07/05Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Unio..
AQ
07/05Novavax, Inc. Announces European Commission Approves Expanded Conditional Marketing Aut..
CI
07/05EMA's CHMP Approves New Manufacturing Site For Active Substance Of COVID-19 Vaccine Nuv..
RE
07/04Novavax Statement on Prototype Vaccine's Broad Immune Responses and Accelerated Focus o..
AQ
07/01Novavax Targets Q4 Release of Omicron-Containing Vaccine; Shares Rise
MT
07/01Novavax expects COVID vaccine targeting Omicron in fourth quarter
RE
06/29Novavax to Participate in Vaccines and Related Biological Products Advisory Committee R..
AQ
06/29BioNTech, Pfizer to starting testing universal coronavirus vaccine in H2
RE
06/29Taiwan to receive first doses of Novavax COVID vaccine this week
RE
06/28Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Respo..
PR
More news
News in other languages on NOVAVAX, INC.
07/05MISE À JOUR SECTORIELLE : Les actions du secteur de la santé en difficulté mardi
07/05MISE À JOUR SECTORIELLE : Les actions du secteur de la santé reculent dans les échanges de..
07/05Novavax déclare que le vaccin COVID-19 est autorisé sous condition dans l'UE pour les a..
07/05Novavax, Inc. annonce que la Commission européenne approuve l'extension de l'autorisati..
07/01Novavax prévoit la mise sur le marché d'un vaccin contenant de l'Omicron au quatrième t..
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 64,29 $
Average target price 149,17 $
Spread / Average Target 132%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-55.06%5 023
MODERNA, INC.-38.76%61 868
IQVIA HOLDINGS INC.-23.69%40 754
LONZA GROUP AG-30.46%40 540
SEAGEN INC.14.34%32 539
CELLTRION, INC.-5.81%19 261